A1C conversion chart: convert A1C to estimated average glucose

Key Takeaways

An A1C conversion chart maps hemoglobin A1C (%) to estimated average glucose (eAG) in mg/dL and mmol/L, reflecting roughly 2-3 months of blood sugar control.

The American Diabetes Association (ADA) diagnostic threshold for diabetes is A1C ≥6.5%; prediabetes ranges from 5.7-6.4%.

An A1C of 7% corresponds to about 154 mg/dL eAG, the ADA target for most adults with diabetes.

Pabau’s digital forms and client records support longitudinal A1C tracking and automated patient follow-up workflows for metabolic health practices.

An A1C conversion chart maps each A1C percentage to its estimated average glucose (eAG) in mg/dL and mmol/L, so you can turn a lab result into a number patients recognize from their own glucose meter. This guide gives you the full conversion chart, the ADA diagnostic thresholds behind it, the ADAG formula that generates it, and how to read it against individualized glycemic targets in practice.

A1C conversion chart: A1C to eAG values

This chart converts an A1C percentage into estimated average glucose (eAG) using the ADA’s validated ADAG equation. Find the patient’s A1C in the first column and read across to the average glucose it represents over the preceding 2-3 months, in both US (mg/dL) and international (mmol/L) units.

These are population averages from the ADAG study, not any single patient’s exact glucose. A specific patient’s meter average can differ, and conditions such as anemia, chronic kidney disease, or hemoglobin variants shift the A1C-to-glucose relationship. Treat the chart as a counseling and interpretation aid, not a substitute for direct glucose monitoring.

What is an A1C conversion chart?

An A1C conversion chart is a clinical reference tool that converts hemoglobin A1C (glycated hemoglobin) percentages into estimated average glucose levels, expressed in both mg/dL (US standard) and mmol/L (international). The interactive version of the same tool is often called an A1C calculator. Either way, it turns a lab result into an actionable glucose target, helping clinicians counsel patients on long-term blood sugar control.

Hemoglobin A1C reflects approximately 2-3 months of average blood glucose exposure due to red blood cell turnover. Unlike point-in-time fingerstick readings, A1C provides a cumulative picture of glycemic control, which is the foundation for diabetes diagnosis, risk stratification, and therapy monitoring.

The American Diabetes Association (ADA) uses A1C as a gold standard for diabetes diagnosis alongside fasting glucose and oral glucose tolerance testing.

Clinicians read an A1C result off the chart to see the corresponding average glucose, then record it in the patient’s chart. In practice management software like Pabau, that value sits in the same medical record as the patient’s history and treatment notes, so you can track it over time and support shared decision-making around therapy adjustments.

How to use an A1C calculator in clinical practice

Converting an A1C result into estimated average glucose takes five straightforward steps that fit into routine diabetes management workflows.

1. Record the patient’s A1C test result: Obtain the lab-reported hemoglobin A1C percentage (or mmol/mol if using IFCC units), billed under CPT code 83036. Confirm the measurement date and ensure the test was performed using an NGSP-certified assay.
2. Enter the A1C value: Input the result in the appropriate measurement unit (NGSP % or IFCC mmol/mol). Most calculators auto-convert between the two standardized formats.
3. Review the corresponding eAG conversion: Read off the estimated average glucose in both mg/dL and mmol/L, showing the blood glucose level the A1C percentage represents over the preceding 2-3 months.
4. Compare to the patient’s glycemic target: The ADA target A1C for most adults is 7% (154 mg/dL eAG). Individualize the target based on patient age, comorbidities, hypoglycemia risk, and life expectancy. Pregnant patients, older adults, and those with advanced kidney disease may have different targets.
5. Document and communicate results: Record the A1C, eAG conversion, and interpretation in the patient record. Use digital forms to capture A1C trends over time, enabling automated follow-up workflows and longitudinal monitoring.

Recording each result in clinical software keeps A1C values in the permanent patient record, searchable for population health reports and available to trigger automated recall campaigns when testing is due.

Who should use an A1C calculator?

An A1C conversion chart is a working tool for clinicians across several specialties and practice models who counsel patients on diabetes management, metabolic health, and preventive care.

• Primary care physicians and nurse practitioners: Foundational tool for annual diabetes screening, diagnosis, and monitoring of Type 1 and Type 2 diabetes in routine office visits.
• Metabolic health and functional medicine practices: Support longitudinal glucose tracking and patient education on prediabetes prevention and lifestyle intervention response.
• Weight loss and obesity medicine specialists: Demonstrate A1C improvement with lifestyle modification or pharmacotherapy (GLP-1 receptor agonists, SGLT2 inhibitors, metformin) during treatment monitoring, particularly for patients coded with morbid obesity (ICD-10 E66.01).
• Endocrinologists and diabetes educators: Core tool for insulin dose titration, therapy intensification decisions, and patient-centered goal setting at routine follow-up visits.
• Wellness and longevity practices: Use A1C conversion data to educate patients on metabolic aging and the cardiometabolic implications of prediabetic A1C ranges.

Benefits of using an A1C calculator

Working from an A1C conversion chart or calculator delivers several operational and clinical benefits that improve patient understanding and support better metabolic health outcomes.

Clarity for patient education: Converting an abstract lab percentage (for example, 8.2%) into a relatable glucose equivalent (189 mg/dL) helps patients visualize their control and understand therapy targets. This builds motivation for adherence to lifestyle changes or medication regimens.

Accurate therapy monitoring: A1C reflects long-term control, so regular monitoring helps clinicians detect therapeutic drift before hyperglycemic complications emerge. A shared conversion reference standardizes interpretation across your practice team, reducing ambiguity in therapy adjustments.

Workflow efficiency: Automated A1C-to-eAG conversion eliminates manual calculation errors and speeds up patient counseling. Embedding the reference in patient portals or staff dashboards reduces documentation time and supports data-driven decisions.

Population health insights: A1C data supports aggregate reporting on cohort-level glycemic control, identifying high-risk patients for proactive recall and intensified monitoring. Many metabolic health practices pair A1C trend data with patient recall software to demonstrate treatment efficacy to payers and insurers.

A1C diagnostic ranges and interpretation

The American Diabetes Association establishes three diagnostic categories based on A1C levels, each carrying different clinical implications and recommended follow-up pathways. Coding for a confirmed diagnosis ranges from Type 2 diabetes without complications (E11.9) to Type 2 diabetes with hyperglycemia (E11.65) or diabetic neuropathy (E11.40), depending on associated complications.

• Normal A1C: below 5.7% – No diabetes. Screening is recommended for adults 35 and older, per current ADA Standards of Care, or earlier for at-risk populations.
• Prediabetes: 5.7-6.4% – Elevated risk for progression to Type 2 diabetes. Recommend a structured lifestyle intervention (150 min/week moderate-intensity activity, 5-7% weight loss). Consider metformin for high-risk patients (for example, BMI over 35, age under 60, or family history of diabetes).
• Diabetes: A1C ≥6.5% – Diagnostic for Type 1 or Type 2 diabetes. Initiate pharmacotherapy per ADA Standards of Care, with individualized A1C targets: 7% for most adults; 6.5% for pregnancy-capable or preconception patients; and a less stringent 7.5-8% for patients with established cardiovascular disease or extensive comorbidities, reflecting the higher hypoglycemia risk of tighter control in this group.

A1C may read falsely low in patients with conditions such as sideroblastic anemia, hemoglobin variants (HbS, HbC), or iron deficiency anemia, and falsely high in chronic kidney disease or post-transfusion states. Follow-up testing with fasting glucose or an oral glucose tolerance test is warranted when clinical suspicion conflicts with the A1C result.

A1C to eAG conversion: the ADAG formula

The ADAG (A1C-Derived Average Glucose) consensus equation is the mathematically validated relationship behind every value in the conversion chart above. The formula is:

A1C (%) = (mean plasma glucose in mg/dL + 46.7) / 28.7

Rearranged to solve for glucose: eAG (mg/dL) = (A1C × 28.7) − 46.7

This relationship was derived from the ADAG study, which combined continuous glucose monitoring and frequent self-monitoring data across 507 subjects (268 with Type 1 diabetes, 159 with Type 2 diabetes, and 80 without diabetes) recruited from 10 international centers.

The study established a consistent A1C-to-glucose correlation across populations. An A1C of 7% approximates 154 mg/dL eAG, and an A1C of 8% equals roughly 183 mg/dL.

International users may work in IFCC units (mmol/mol) rather than NGSP percentages. Modern A1C calculators auto-convert between formats using: IFCC mmol/mol = (NGSP % − 2.15) × 10.929.

Supporting educational resources for your practice

Beyond the conversion chart, several complementary resources reinforce patient understanding of glucose control. Staff-led sessions on A1C interpretation, diet-glucose relationships, and medication adherence increase engagement. Printable A1C reference charts posted in exam rooms and patient care areas act as visual touchpoints that reinforce targets during consultations.

The CDC’s National Diabetes Prevention Program and the ADA’s Standards of Care provide evidence-based lifestyle and pharmacotherapy guidelines you can reference in patient education materials. Patient portals can deliver automated A1C trend notifications, appointment reminders, and educational articles when lab results are logged, reducing clinician workload and improving adherence monitoring.

Metabolic health practices using automated workflows often build A1C-triggered recall pathways. When a patient’s A1C drops into the prediabetic range after a lifestyle intervention, an automated email congratulates the patient and schedules follow-up counseling, which supports retention and helps reduce missed follow-up appointments.

Transform Your Metabolic Health Practice

See how Pabau's patient records, automated workflows, and clinical dashboards help metabolic health practices track A1C trends, automate follow-up care, and improve patient engagement across your practice.

Book a demo

Conclusion

An A1C conversion chart is a foundational clinical asset for diabetes diagnosis, risk stratification, and longitudinal management in primary care, metabolic health, and weight loss practices. Converting A1C percentages into estimated average glucose (eAG) helps patients visualize their glycemic control and motivates behavior change.

Because the ADAG-based conversion holds across patient populations, the chart is reliable for screening, diagnostic workups, and therapy monitoring, as long as you account for the conditions that skew A1C.

Record conversions in the digital patient record, automate follow-up workflows triggered by A1C thresholds, and use longitudinal A1C tracking to demonstrate population health outcomes to your team and payers.

Pabau’s integrated clinical documentation and metabolic health reporting support A1C monitoring at scale, helping you deliver personalized, data-driven diabetes care. Book a demo today to see how Pabau fits your diabetes care workflow.

Continue your research

List Item #1

List Item #2

Frequently asked questions